Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Prenetics Global (PRE) reported Q3 2026 revenue of $64.1 million, above the high end of its guidance. Total revenue rose about 228% year over year, and IM8 revenue rose about 266% to $62.9 million. The quarterly loss was $25.4 million, while the adjusted EBITDA loss improved to 20% of revenue from 39% in Q2.
Prenetics reaffirmed FY 2026 total revenue guidance of $220–230 million and FY 2027 IM8 revenue guidance of at least $400 million. It now expects a second-half 2026 adjusted EBITDA loss of $30–35 million, versus $8–12 million previously, as it spends more to acquire customers.
Operations used $27.5 million in cash. Adjusted free cash flow was positive at $4.1 million after including $31.6 million in net facility funding. IM8's first full-quarter customer group generated gross profit of about 4.1 times its acquisition cost in under two years.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointGeneral Catalyst funding commitment totals $1 billion, with $31.6 million in net funding in Q3 3.1× market cap
- Moderate pointQ3 total revenue rose about 228% year over year to $64.1 million, beating guidance of $63–64 million
- Moderate point. Forward-looking: it has not happened yet and may not happen.FY 2027 IM8 revenue guidance was held at $400 million or more, based on products already on sale
- Moderate point. Forward-looking: it has not happened yet and may not happen.FY 2026 revenue guidance was held at $220–230 million overall, including $215–222 million for IM8
- Moderate pointQ3 adjusted EBITDA loss was $12.7 million, or 20% of revenue, improved from 39% in Q2
- Moderate pointQ3 contribution profit was $30.6 million, a 48% margin before acquisition marketing and brand-partner costs
- Moderate pointCustomer acquisition cost fell for a second straight quarter to approximately $285 despite record acquisition spending
9 minor points
- Minor pointQ3 IM8 revenue rose about 266% year over year to $62.9 million, its seventh consecutive record quarter, beating guidance of $61.5–62.5 million
- Minor pointCash and current financial assets rose to $111.5 million at September 30 from $109.4 million at June 30
- Minor point. Forward-looking: it has not happened yet and may not happen.Adjusted free cash flow was positive at $4.1 million in Q3 and is expected to remain positive
- Minor pointIM8 annualized revenue pace reached approximately $284 million based on record September revenue of $23.7 million
- Minor point. Forward-looking: it has not happened yet and may not happen.IM8 year-end 2026 annualized revenue pace guidance was reaffirmed at $300 million or more
- Minor pointIM8's 27,000 Q1 2025 customers generated about 4.1 times their acquisition cost in gross profit in under two years
- Minor point. Forward-looking: it has not happened yet and may not happen.IM8's next 91,000 customers are on pace to reach the 3-to-1 gross-profit-to-acquisition-cost benchmark in early 2027
- Minor pointCustomer acquisition payback is about six months at current costs, by Prenetics' estimate
- Minor point. Forward-looking: it has not happened yet and may not happen.IM8 retail and China expansion is planned by the end of 2027
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Second-half 2026 adjusted EBITDA loss guidance widened to $30–35 million from $8–12 million as customer acquisition spending increases
- Major pointQ3 loss totaled $25.4 million, including a $7.2 million noncash loss from revaluing warrant liabilities 8% of market cap
- Moderate pointOperating activities used $27.5 million in cash in Q3
- Minor pointAdjusted free cash flow depends on continued General Catalyst funding and does not measure cash generated by operations
News Explained
Positive adjusted free cash flow depends on continued facility funding and is not a measure of operating cash generated or discretionary residual cash.
Prenetics reported Q3 2026 results and reaffirmed
The company expects Adjusted Free Cash Flow to remain positive, but defines it as operating cash flow less capital expenditures plus net fundings under the General Catalyst facility. The measure depends on continued facility funding and is not cash generated from operations or residual cash available for discretionary use.
Key Figures
- Total revenue
- $64.1 million
- Q3 2026; up ~228% YoY and above $63–64 million guidance
- IM8 revenue
- $62.9 million
- Q3 2026; up ~266% YoY and above $61.5–62.5 million guidance
- Loss for the period
- $25.4 million
- Q3 2026; includes a $7.2 million non-cash fair-value loss on warrant liabilities
- Adjusted EBITDA
- $12.7 million loss
- Q3 2026; (20)% of revenue, improved from (39)% in Q2
- Adjusted Free Cash Flow
- $4.1 million positive
- Q3 2026
- FY2026 total revenue guidance
- $220–230 million
- Reaffirmed
- Second-half 2026 Adjusted EBITDA outlook
- $30–35 million loss
- Expected, compared with the $8–12 million loss expected in August
- FY2027 IM8 revenue guidance
- $400 million+
- Reaffirmed
Historical Context
-
Q2 IM8 revenue was $45 million, establishing a comparable baseline for the Q3 revenue report.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ebitda financial
ifrs financial
warrant liabilities financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
— Total revenue of
— IM8 revenue of
— September was the strongest month ever at IM8, with
— Loss for the period of
— Positive Adjusted Free Cash Flow of
— Cash and current financial assets of
— The 27,000 customers IM8 acquired in Q1 2025, its first full quarter, have returned approximately 4.1x their acquisition cost in gross profit in under two years, above the 3-to-1 benchmark, and the next 91,000 are on pace to reach it in early 2027
— Customer Acquisition Cost3 declined for the second consecutive quarter, to approximately
— Reaffirms FY2026 total revenue guidance of
— Second-half 2026 Adjusted EBITDA loss now expected at
WEBCAST INFORMATION
Prenetics will host a live earnings webcast at 8:30 a.m. Eastern time today to discuss the results. To join, please visit https://stocktwits.com/symbol/PRE. A replay will be made available on the Investor Relations website following the call.
NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (Nasdaq: PRE) (“Prenetics” or the “Company”), a leading consumer health company and parent of the AI-native direct-to-consumer wellness brand IM8, co-founded by Sir David Beckham, today reported its third quarter 2026 financial results. The complete results are presented in Prenetics’ Q3 2026 Letter to Shareholders (the “Shareholder Letter”), which includes all financial tables, together with an accompanying Q3 2026 Investor Presentation (the “Investor Presentation”), each dated November 18, 2026 and available on the Company’s Investor Relations website at https://ir.prenetics.com.
Danny Yeung, Co-Founder and CEO of Prenetics and IM8, said: “This was a record quarter, with revenue above the top of our guidance, and our case for investing in IM8 has never been clearer. So we are investing more. The 27,000 customers we acquired in our first full quarter have already returned about 4.1 times their acquisition cost in gross profit, in under two years, buying only our core products. That is gross profit already collected, not a forecast, and three to one is the benchmark subscription businesses are widely measured against. The next 91,000 customers are on pace to pass it in early 2027. Customers we acquire at today’s cost are earning it back in about six months, and independent card data shows our customers staying longer than those of the three leading brands we are compared with, as we detail in our Shareholder Letter and Investor Presentation. Returns like these are why we now expect a second-half Adjusted EBITDA loss of
“We are making that choice from strength. We ended the quarter with
Brian Rosin, Chief Financial Officer Designate of Prenetics, said: “Six months into my role at IM8, what stands out is how well the numbers hold up when you take them apart, cohort by cohort. It is rare to see growth at this rate with returns that can be measured this precisely. This quarter, revenue came in above the top of the range we gave in August, Customer Acquisition Cost declined for the second consecutive quarter while we spent more, and Adjusted EBITDA improved to a loss of
OUTLOOK
The Company’s outlook as of the date of this press release is as follows:
Fiscal year 2026 revenue: total revenue of
Second-half 2026 Adjusted EBITDA: a loss of
IM8 Annualized Revenue Run-Rate at year-end 2026:
Adjusted Free Cash Flow, a non-IFRS liquidity measure: expected to remain positive. Adjusted Free Cash Flow includes net fundings under the General Catalyst Customer Value Fund facility, and is not a measure of cash generated from operations.
Fiscal year 2027 IM8 revenue:
Planned launches, none of which is included in the guidance above: IM8 Hydration in the first quarter of 2027; Care Bears by IM8 in the first half of 2027; and entry into retail and China by the end of 2027.
All financial tables, cohort economics, customer acquisition metrics, independent third-party card data, the Company’s long-term financial framework, and management’s full discussion and outlook are contained in the Shareholder Letter and the Investor Presentation, which investors are encouraged to review in full.
ABOUT PRENETICS
Prenetics Global Limited (Nasdaq: PRE) is a leading consumer health company on a mission to advance human health and longevity. Its flagship brand, IM8, co-founded with Sir David Beckham, is redefining premium daily nutrition through science-backed formulations — anchored by Daily Ultimate Essentials, a 90-ingredient daily nutrition system that is NSF Certified for Sport and clinically studied. IM8 is the fastest-growing premium supplement brand ever recorded, reaching approximately
ABOUT IM8
IM8 is a premium health and longevity brand co-founded by Sir David Beckham and built with an elite team of scientists spanning medicine, academia and space science. Its flagship product, Daily Ultimate Essentials, delivers 90 ingredients in a single daily sachet – engineered to replace 16 different supplements in one drink – and is NSF Certified for Sport, non-GMO, vegan, free from common allergens and contains no artificial flavors, colors or sweeteners. Launched in December 2024, IM8 ships to 46 countries and has delivered more than 70 million servings. The brand is backed by a roster of global partners and ambassadors including Giannis Antetokounmpo, Aryna Sabalenka, Lily Collins, Jay Shetty, Ollie Bearman, Diplo, Inter Miami CF and the NBA. IM8 is a wholly owned subsidiary of Prenetics Global Limited (Nasdaq: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more, visit www.IM8health.com.
CONTACTS
Investor Relations: ir@prenetics.com
Media: press@prenetics.com
FORWARD-LOOKING STATEMENTS AND DATA NOTES
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance reflects management’s current estimates and assumptions as of the date of this press release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the impact of the Customer Investment Agreement with GC Customer Value Arranger, LLC is unpredictable, and the arrangement may not function as expected, and its failure to do so could materially and adversely impact our financial condition and results of operations, we may require additional capital to grow our business, which may not be available on terms acceptable to us or at all, the Company may not be able to maintain and enhance its IM8 business and brand if it suffers negative publicity or fails to maintain a strong base of engaged customers and content creators, or otherwise fails to meet customers’ expectations; the Company’s ability to further develop and grow its business, including new products and services; and the Company’s ability to efficiently and effectively deploy financial and management resources towards maintaining and growing the business. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law. Nothing in this press release constitutes an offer to sell, or the solicitation of an offer to buy, any securities of the Company.
Certain operational data, customer metrics, market data, and industry information included in this press release are derived from management records, internal analyses, third-party sources, and management's understanding of the markets in which the Company operates. Operational data is unaudited and may differ from data presented in the Company’s reports filed or furnished with the U.S. Securities and Exchange Commission. Cohort figures are preliminary, unaudited, based on management billing records, and reflect gross billings rather than IFRS revenue. The return of approximately 4.1x is for the 27,000 customers the Company acquired in the first quarter of 2025 and is cumulative gross profit at the Company’s actual gross margin divided by the acquisition marketing for that cohort (approximately 3.75x at the
BASIS OF PRESENTATION
Figures for prior periods have been re-presented in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations (“IFRS 5”). As part of the Company’s strategic repositioning to focus its resources and capital allocation on its core consumer health and prevention businesses, the Company has divested or exited certain non-core businesses and investments, including ACT Genomics, Europa and Insighta.
In June 2025, the Company determined that ACT Genomics Holdings Company Limited (“ACT Genomics”) met the criteria to be classified as held for sale and a discontinued operation, following the signing of a definitive sale and purchase agreement with Delta Electronics, Inc. and its results have been excluded from the Company’s continuing operations thereafter. The divestment of ACT Genomics was completed on October 1, 2025.
The Company also completed the divestiture of substantially all of the assets of its Europa business in January 2026 and determined that Europa met the criteria to be classified as held for sale and a discontinued operation. Accordingly, Europa’s results are included in the Company’s financial results only up to the date of completion of the divestiture and are excluded from the Company’s continuing operations thereafter.
In February 2026, the Company completed the disposal of its remaining equity interest in Insighta Holdings Limited (“Insighta”). Accordingly, the Company’s share of results from Insighta is included only up to the date of completion of the disposal. The disposal of remaining equity interest in Insighta was completed on February 13, 2026.
In accordance with IFRS 5, the results of discontinued operations are presented separately from the Company’s continuing operations (comprising IM8 and CircleDNA) in the unaudited consolidated statements of profit or loss and other comprehensive loss, and comparative figures for those statements have been re-presented accordingly.
The financial information presented in this press release is unaudited. Unaudited non-IFRS financial measures have been provided in this press release. An explanation of these measures is included below under the heading “Unaudited Non-IFRS Financial Measures”.
UNAUDITED NON-IFRS FINANCIAL MEASURES
To supplement the Company’s consolidated financial statements prepared in accordance with International Financial Reporting Standards (IFRS), the Company is providing the following non-IFRS measures: EBITDA, Adjusted EBITDA, Contribution Profit, Contribution Margin and Adjusted Free Cash Flow. These non-IFRS financial and liquidity measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-IFRS financial and liquidity measures are useful to investors in evaluating the Company’s ongoing operating results and trends and in facilitating period-to-period comparisons of the Company’s performance.
EBITDA is defined as loss for the period under IFRS Accounting Standards before (1) depreciation and amortization, (2) interest income, (3) other finance costs, and (4) income tax expense.
Adjusted EBITDA is defined as EBITDA further adjusted to exclude (1) amortization of deferred expenses, (2) equity-settled share-based payment expenses, (3) transaction-related expenses associated with acquisition, disposal and fundraising activities, (4) strategic realignment and discontinued products impact, (5) exchange gain or loss, net, (6) fair value (gain)/loss on financial assets at fair value through profit or loss, (7) fair value (gain)/loss on warrant liabilities, (8) unrealized fair value loss on digital assets, (9) realized fair value gain on digital assets, and (10) (profit)/loss from discontinued operations, net of tax.
Contribution Profit is defined as Adjusted EBITDA further adjusted to exclude acquisition marketing expenses, brand royalty, and ambassador contracts and licensing fees.
Contribution Margin, a non-IFRS financial measure, is calculated as Contribution Profit divided by revenue. Management believes Contribution Profit and Contribution Margin are useful to investors because they present the profitability of the business before growth investment. Growth investment comprises (1) customer-acquisition marketing, which is discretionary in timing and amount and which management evaluates as a capital-allocation decision against expected cohort returns, funded in part through the CVF facility; and (2) brand royalty and ambassador contract and licensing costs, which, while contractually committed, represent investments in long-term brand equity entered into to support that growth strategy rather than costs of serving the existing customer base. These measures have limitations: growth investment has been and will continue to be a significant recurring cash expense, brand royalty varies with revenue, and Contribution Profit should not be viewed as profitability achievable absent such spending.
Adjusted Free Cash Flow, a non-IFRS liquidity measure, is defined as net cash (used in) from operating activities determined in accordance with IFRS Accounting Standards, less capital expenditures, plus net fundings under the General Catalyst Customer Value Fund (CVF) facility. This non-IFRS liquidity measure depends on the continued availability of the CVF facility funding, and is not a measure of cash generated from operations, and does not represent residual cash available for discretionary use. “Net fundings” represents, for the relevant period, funding amounts received under the CVF facility (“Investment Amounts,” as defined in the Customer Investment Agreement dated July 13, 2026) less repayments of Investment Amounts and interest paid under the facility.
In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management, or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company’s non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS Accounting Standards.
The Company has not reconciled its outlook for Adjusted EBITDA to loss for the period or Adjusted Free Cash Flow to net cash (used in) from operating activities, their most directly comparable measures under IFRS Accounting Standards. Items such as fair value changes on warrant liabilities and financial assets, share-based payment expenses, and the timing of funding and repayments under the General Catalyst facility cannot be predicted with reasonable certainty. Accordingly, these reconciliations are not available without unreasonable effort. These items could materially affect the corresponding IFRS results.
Investors are encouraged to review the reconciliation of Adjusted Free Cash Flow set forth below and the reconciliations set forth in the Shareholder Letter under the captions “Reconciliation of Loss for the Period Under IFRS Accounting Standards and Adjusted EBITDA (Non-IFRS)” and “Reconciliation of Adjusted EBITDA (Non-IFRS) and Contribution Profit (Non-IFRS).”
CASH FLOW SUMMARY AND RECONCILIATION OF ADJUSTED FREE CASH FLOW (NON-IFRS)
The following table summarizes the Company’s cash flows (used in) from operating, investing and financing activities under IFRS Accounting Standards:
| (in thousands of U.S. dollars; unaudited) | Three months ended September 30, 2026 | Three months ended June 30, 2026 (restated) | Three months ended September 30, 2025 | ||||||
| Net cash (used in)/from operating activities | $ (27,512 | ) | $ (13,731 | ) | |||||
| Net cash from/(used in) investing activities | 489 | 41,679 | (6,873 | ) | |||||
| Net cash from/(used in) financing activities | 31,430 | (24,923 | ) | (918 | ) | ||||
The following table reconciles net cash (used in) from operating activities under IFRS Accounting Standards to Adjusted Free Cash Flow, a non-IFRS liquidity measure:
| (in thousands of U.S. dollars; unaudited) | Three months ended September 30, 2026 | Three months ended June 30, 2026 (restated) | Three months ended September 30, 2025 | |||||
| Net cash (used in)/from operating activities under IFRS Accounting Standards | $ (27,512 | ) | $ (13,731 | ) | ||||
| Less: capital expenditures | — | — | — | |||||
| Add: net fundings under CVF facility (a) | 31,594 | — | — | |||||
| Adjusted Free Cash Flow (non-IFRS) | $ 4,082 | $ (13,731 | ) | $ 873 | ||||
(a) Net fundings under the CVF facility comprise funding received of
__________________________
1 Annualized Revenue Run-Rate ("ARR") is an operating metric calculated by multiplying IM8 revenue recognized in the applicable month by twelve and includes revenue from both subscription and one-time purchases. ARR is not a financial measure under IFRS, and is not necessarily indicative of revenue for any future period. ARR reflects orders from both new and existing customers and incorporates the effect of cancellations and non-renewals occurring on or before the applicable month; however, it does not adjust for anticipated future cancellations, non-renewals or pauses. ARR annualizes a single month of revenue and assumes that the revenue recognized in that month is maintained for the following twelve months. As a result, ARR is sensitive to the timing of promotional activity, product launches and billing cycles. In particular, the full order value of quarterly subscription plans is recognized upon shipment of the three-month supply, which increases revenue recognized in months when quarterly billings are concentrated. It may therefore differ significantly from actual future revenue.
2 See definitions for “Contribution Profit” and “Contribution Margin” in the section “Unaudited Non-IFRS Financial Measures” below.
3 Customer Acquisition Cost (“CAC”) is an unaudited operating metric calculated as acquisition marketing divided by the number of new customers acquired in the period. Acquisition marketing comprises advertising and media, influencer, commissions, sponsorships, agency fees and other related working and non-working marketing expenses as incurred; it excludes marketing personnel and licensing and royalty fees. New customers include subscription and one-time orders across all channels, products and plan types.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.